Promoter DNA methylation, which occurs on cytosine nucleotides across CpG islands, results in gene silencing and represents a major epigenetic alteration in human cancer. Methylation-specific PCR can amplify these modifications as markers in cancer cells. In the present work, we rigorously review the published literatures describing DNA methylation in the promoters of critical tumor suppressor genes; detection of promoter DNA methylation in various body fluids permits early detection of cancer cells during perioperative courses of clinical treatment. The latest whole-genome comprehensive explorations identified excellent epigenetic biomarkers that could be detected at high frequency with high specificity; these biomarkers, which are designated highly relevant methylation genes (HRMG), permit the discrimination of tumor tissues from the corresponding normal tissues; these markers are also associated with unique cancer phenotypes, including dismal prognosis. In humans, HRMG include the CDO1, GSHR, RASSF1 and SFRP1 genes, with these markers permitting discrimination depending on the organs tested. The combination of several HRMG increased the early detection of cancer and exhibited reliable surveillance potential in human body fluids. Cancer clinics using such epigenetic biomarkers are entering a new era of enhanced decision-making with the potential for improved cancer prognosis.
K E Y W O R D S
body fluid, cancer, CDO1, methylation, tumor suppressor gene and HDAC inhibitors in cancer cell lines reactivate silenced TSG expression. Techniques such as pharmacological unmasking microarrays (PUM) have been used to identify novel, critical TSG candidates. 4 Nevertheless, frequent cancer-specific methylation is rare across the whole genome, and few methylated genes have been validated as sites of its frequent aberration with high specificity in human cancer. [5] [6] [7] Rigorous screening by PUM has repeatedly unveiled novel cancer-prone methylation genes associated with tumor suppressive functions, such as the encoding homeobox only protein homeobox (HOPX) gene has been identified in various cancers, [8] [9] [10] [11] [12] and HOPX expression has been independently revealed to be a biomarker representing differentiation or quiescent stem cell signatures in normal organ tissues. [13] [14] [15] [16] [17] Hence, epigenetic changes in differentiation markers may be essential for the initiation of cancer cell growth.
DNA methylation in primary cancer tissues does not necessarily represent cancer-specific methylation. For example, actual cancer specificity has been confirmed only in a very limited number of genes in primary gastric cancer. 9 In a screen that used direct sequencing to distinguish the "wheat" (genes with cancer-specific methylation) from the "chaff" (other methylated genes), HOPX was selected with the highest ranking (frequently methylated in 90% of primary tumors), followed by Reprimo (80%) and NMDAR2B (70%);
high-throughput analysis using quantitative methylation-specific PCR (Q-MSP) validated these priorities. 9, 18 Q-MSP can be used to screen for such cancer specificity because of its high-throughput nature; recent searches for the best performance showed high (exceeding .9) area under curve (AUC) values in human cancer for genes like that encoding cysteine dioxygenase 1 (CDO1). 19 Among many other promising genes that have also been reported to be methylated in primary tumor tissues, few have been validated for their cancer-prone nature using the "gold standard" method, Q-MSP.
Such candidate biomarkers for methylated genes are widely scattered across the entire genome, amounting to a total of 200-300 genes. 6, 8, 20 After rigorous validation, superior biomarker candidates representing cancer-specific methylation are now considered ready for use in clinical decision-making in the development of therapeutic strategies, with possible use extending even to cases where cancer surgery is indicated. 21 In the present review article, the realistic potential of the epigenetic markers in cancer clinics is described.
| ME THYL ATI ON A SSAY

| Direct sequencing
Bisulfite treatment of DNA converts unmethylated cytosine to thymine without yielding a change to methylated cytosine. Following PCR amplification of the bisulfite-treated sequences, direct sequencing (ie, without first cloning the fragment) permits "direct" visualization of either the cytosine or thymine. This method is appealing for discovery screening of novel methylation events that represent novel TSG in primary tumors, [4] [5] [6] [7] as well as the clear differentiation of primary tumors from the corresponding normal tissues (Figure 2A ).
In addition to direct sequencing, cloned sequencing (ie, sequencing of individual fragments after cloning of the PCR products) can elucidate the fine-scale mapping of methylation of the cytosines 21, 22 ( Figure 2B ). However, cloned sequencing can be costly (in both time and money) and so is inappropriate for high-throughput analysis. 
| Real-time methylation-specific PCR
Methylation-specific PCR (MSP) is appropriate for highthroughput analysis of DNA methylation, 23 and quantitative MSP using a TaqMan probe (Q-MSP) permits the investigation of both the tumor tissues and the corresponding normal tissues of cancer patients in a high-throughput manner; evaluation of the resulting receiver operating characteristic (ROC) curves permits discrimination of the tumor from the normal mucosa based on the most objective optimal criterion (optimal cut-off value). 9, 18 The AUC of the ROC curve is a "gold standard" for identifying excellent epigenetic cancer biomarkers. However, Figure 2B . 22 These results demonstrate that hypomethylation is not synonymous with complete unmethylation.
At best, Q-MSP can detect methylation at dilution levels 1/1000 that of full methylation ( Figure 2C ), although Q-MSP is unable to detect a 1/10 000 to 1/100 000 dilution of methylation, a detection level that would be equivalent to that of digital PCR technique that is the most sensitive system available at present. 21, 24 However, there are currently few papers on the use of digital PCR for methylation analysis in cancer clinics.
| THE B E S T PERFORMAN CE A S AN EPI G ENE TI C C AN CER B I OMARK ER : CD O1
Cancer-specific methylation should be designated only after comparing methylation in tumor tissues with that of the corresponding non-cancerous tissues. Nevertheless, many methylation genes have been so-called without such validation. CpG island methylator phenotype (CIMP) was defined based on the methylation profiles of multiple well-known tumor suppressor genes (e.g.
p16, MLH1
and TIMP3) in the same tissue samples; however, the individual genes showed methylation frequency of <50% in most primary tumors. 25, 26 Such methylation frequencies are rather low compared to the >60% methylation seen in human cancer loci recently identified as highly relevant methylation genes (HRMG). 27 The relations of the CIMP phenotype to HRMG methylation status in human cancer have remained elusive, although several reports have suggested that HRMG are closely associated with CIMP. For example, methylation of RIZ1, an HRMG in gastric cancer (hypermethylated in 69% of primary tumors), was closely associated with the CIMP phenotype (P = .002). 28 While HRMG differ in various organs (Table 1) , and the CDO1 gene is one of the most common HRMG reported to data. The story thus begins at the CDO1 gene followed by other HRMG.
Cysteine metabolism plays a pivotal role in cell stemness through regulation of reactive oxygen species (ROS), 29 cancer. 44 The frequencies of the aberrations in CDO1 methylation in these cancers are high ( Figure 3A) . Intriguingly, however, there are several unique cancers in which the CDO1 gene did not show an HRMG phenotype: for instance, renal cell clear carcinoma. 28 The frequencies were largely determined by generating an ROC curve to determine the most optimal cut-off value of methylation after comparing the tumor with the corresponding normal tissues in Q-MSP; an example of such as analysis is shown in Figure 3B for pancreatic cancer. 43 In contrast, the clinical relevance of CDO1 gene in primary tumor tissues has also been demonstrated in several cancers.
Specifically in esophageal cancer, CDO1 methylation was significantly higher in advanced SCC tumors with cStage II/III than in the superficial tumors with cStage I, 36 and was significantly higher in larger-sized adenocarcinomas than in smaller-sized adenocarcinomas. 37 Aberrant methylation of the CDO1 gene accumulated as the tumor progressed, as demonstrated in colorectal 38 and gallbladder tumorigenesis 44 ( Figure 4A ,B). These findings indicate that promoter DNA methylation of the CDO1 gene commonly accumulates with progression in human cancers.
Cases with CDO1 hypermethylation also showed poorer prognosis than those with hypomethylation in primary breast, 34 prostate, 41 colorectal, 38 gallbladder 44 and esophageal cancers. 36, 37 Interestingly, in primary breast cancer, CDO1 hypermethylation did not correlate significantly with markers of tumor progression such as TNM factors, while CDO1 hypermethylation was the strongest independent prognostic factor. 34 Importantly, the prognostic relevance of CDO1 methylation was confirmed even in a prospective nationwide cohort study in the Netherlands of patients with renal cell carcinoma. 40 These findings suggest that the methylation status of the CDO1 gene could be used as a prognostic marker in various human cancers.
However, the cut-off values of CDO1 methylation as prognostic markers were always higher than those used to discriminate the tumors from the corresponding normal tissues, suggesting that cancer progression resulting in dismal prognosis is associated with stronger epigenetic changes than those observed at initial tumorigenesis. F I G U R E 3 A, Methylation of the CDO1 gene is shown in order of the frequencies in various cancers of esophageal adenocarcinoma (100%), endometrial adenocarcinoma (98%), pancreatic adenocarcinoma (94%), large intestine adenocarcinoma (CRC; 91%), stomach (gastric) adenocarcinoma (87%), esophageal squamous cell carcinoma (SCC) (83%), lung (non-small cell) cancer (82%), breast adenocarcinoma (72%), bladder cancer (78%), biliary tract cancer (73%), gallbladder cancer (72%) and kidney cancer (38%). B, Area under curve (AUC) of the receiver operating characteristic (ROC) curve to discriminate primary tumor tissues from the corresponding normal tissues is shown for pancreatic cancer. Quantitative methylation-specific PCR (Q-MSP) showed significant difference (P < .0001) in CDO1 methylation between the primary tumor tissues and the corresponding normal tissues
TA B L E 1 Methylation frequencies of highly relevant methylation genes (HRMG) in human cancers
PAX1 (.89, 100%) Esophageal adenocarcinoma SFRP1 (96%) CDO1 (95%) APC (92%) CDH1 (84%) TIMP3 (74%) Lung GHSR (1.0) CDO1 (.87, 92%) HOXA9 (96%) SHOX2 (94%) TAC1 (87%) Stomach CDO1 (.
| C AN CER DE TEC TI ON MARKER OF CD O1 G ENE ME THYL ATI ON IN H UMAN BODY FLUIDS OR CONVENTIONAL B IOPSY/ C Y TOLOGY TE S T
Highly relevant methylation genes could also be used as detec- Cervical scrapings were reported as a potential source of material for molecular testing in endometrial cancer, and CDO1 hypermethylation amazingly showed an 82% sensitivity with 94% specificity for detecting endometrial cancer in cervical scrapings. 42 DNA testing using CDO1 hypermethylation may be useful for intraoperative diagnosis in gastric cancer surgery. The peritoneal DNA cytology test-positive gene (CY1) is a critical prognostic marker of gastric cancer, and CY1-positive cases represent stage IV disease. However, the conventional cytology test does not achieve sufficient sensitivity because peritoneal recurrences have been recognized in cytology-negative (CY0) cases. DNA cytology testing using CDO1 methylation showed 2-fold higher detection rates of the minimal residual disease than did conventional CY tests in F I G U R E 4 Methylation value increased as the tumor progressed. A, In colorectal carcinogenesis, the CDO1 methylation level increased significantly during the course of Vogelstein adenoma carcinoma sequence (P < .0001). B, In gallbladder carcinogenesis, the CDO1 methylation level increased significantly as the disease progressed from stage I to stage II the peritoneum, which was all positive for CY1 cases ( Figure 5A ), and can predict peritoneal recurrence accurately. 50 DNA CY1 diagnosis in the peritoneum would be beneficial for planning future multimodal therapy in gastric cancer after curative surgery.
Cytology tests targeted at the peritoneum are critical for other types of cancer, such as colorectal 51 or ovarian cancer, 52 and DNA CY1 information may be useful for decision-making in the context of various abdominal cancers other than gastric cancer.
CDO1 methylation could also be used to evaluate conventional biopsy samples evaluating tumor eradication after neoadjuvant therapy in esophageal cancer. 36 In esophageal SCC showing histological grade 2/3 that has been treated with neoadjuvant chemotherapy, the CDO1 methylation level is significantly lower than in other cases ( Figure 5B ). 
| CLINICAL DECISION BY COMBINATION OF HIGHLY RELEVANT METHYLATION GENE EPIGENETIC BIOMARKERS
Epigenetic biomarkers using HRMG can affect the accuracy of: (i) preoperative diagnosis; (ii) intraoperative diagnosis; (iii) pathological diagnosis; and (iv) follow-up surveillance on the therapeutic decision in cancer clinics.
| Preoperative diagnosis
In hepato-pancreato-biliary (HPB) cancer, pancreaticoduodenectomy, which has a high mortality rate, is needed for cure, and surgeons would prefer to definitively confirm cancer preoperatively.
However identified HRMG with higher performance in pancreatic cancer than CD1D, including the GHSR 54 and CDO1 43 genes (Table 1) . Liquid biopsy of pancreatic juice using such novel HRMG (or combinations thereof) holds great promise.
In biliary tract cancer (BTC), bile solution was used to detect cancer using CDO1/CNRIP1/SEPT9/VIM methylation. 49 These genes were HRMG of BTC, and the combination detection in bile solution showed 85% sensitivity with 95% specificity. The AUC of the combination yielded an AUC of .94, but CDO1, the marker with the best performance, also exhibited an AUC of .93. Liquid biopsy using such HRMG showed superior diagnosis (73%-91%) and high specificity (95%-100%) compared to the conventional cytology test (58%-63% methylation combination showed 88% sensitivity with 71% specificity (AUC, .89). 47 These genes were HRMG in lung cancer and increased methylation was detected in the plasma of lung cancer, but the best discrete combination of the methylated genes (CDO1/TAC1/ SOX17) exhibited the highest performance (91% sensitivity with 62% specificity). 47 Relatively low specificity is a concern in lung cancer.
Ooki et al 48 . 57 Colonoscopy is an invasive procedure with a high risk of complications, so a fecal DNA test would be a promising tool for assessment prior to colonoscopy.
In oral cancer, a saliva test using HRMG such as HOXA9/NID2
detected 50% of cancers with 90% specificity. 58 This sensitivity was not satisfactory as a liquid biopsy using HRMG, putatively due to inferior discriminating markers of oral SCC cancer (representing AUC of approximately .8 in primary tumors). However, saliva testing using another combination of HRMG (EDNRB/DCC) yielded improved diagnostic accuracy of oral neoplasms including precancerous lesions when combined with professional classification of clinical risk. 59 In gynecological and urological cancer research, methylation markers were applied to the testing of cervical scrapings and urine specimens. Both tests are kinds of cytological assays, and various methylation markers showed superior clinical outcomes for diagnosis of the individual cancers as described below. This improved performance was especially notable for prostate cancer, where recurrence was defined as biochemical recurrence by serum PSA. These results demonstrate that biomarkers could have a significant role in disease surveillance, beyond the use of imaging modalities.
Screening by HRMG analysis of cervical scrapings using HRMG was applied to both cervical cancer and endometrial cancer. In cervical SCC, SOX1 and PAX1 methylation have been reported to have 74% sensitivity with 97% specificity in scrapings. 60 In combination with the Pap test, the sensitivity reached 89%. 61 Early detection of cancer would improve the clinical outcome of less invasive surgical treatments. However, CADM1/MAL combination analysis showed 92% sensitivity compared to CIN3
and 100% sensitivity for cancer.
62
The HRMG profile of endometrial cancer is different from that of cervical SCC cancer; however, the combination of HRMG showed more successful performance in the former than in the latter. Specifically, the BHLHE22/CDO1/CELF4 combinations of methylation markers showed 92% sensitivity with 95% specificity in scrapings tests. 42 Given that there have been no descriptions of methylation frequencies of primary tumors for assessing whether CDO1 is an HRMG in this disease, that gene was not included as an HRMG for endometrial cancer in Table 1 .
In urological cancers as well as in gynecological cancers, DNA diagnosis in urine sediments has been rigorously explored using HRMG analysis. In bladder cancer, urine sediments using Twist1/ NID2 methylation showed 90% sensitivity with 95% specificity, compared to 48% sensitivity in conventional urine cytology test. 63 In bladder cancer, there is little information regarding the AUC values assessed for both tumor and corresponding normal tissues by Q-MSP for genes such as CDO1.
19
In prostate cancer and renal cell cancer, methylation biomarkers are likely to be promising for early detection of cancer cells. In prostate cancer, the combination of GSTP1/p16/ARF/MGMT methylation in urine sediments showed 87% sensitivity with 100% specificity. 64 In prostate cancer, many excellent HRMG have been reported, 54, 65 and further optimization is anticipated. The CDO1 methylation level is significantly higher in prostate cancer than in benign prostate hyperplasia or normal prostate tissues; however, neither AUC nor frequencies were reported in that study. 41 In gynecological and urological cancer research, comparisons of tumor tissues with the corresponding normal tissues have seldom been investigated, but test samples such as urine sediments or scrapings have been examined directly. To date, it has not been proved whether methylation markers are actually HRMG, although in the present review, the HRMG was defined using AUC of scraping samples. Accurate diagnosis using such HRMG is expected to lead to appropriate treatment strategies including surgery. 71, 72 and other cancers. 73, 74 Brain tumor cases with MGMT hypermethylation exhibited better postoperative outcomes than those with MGMT hypomethylation. Specifically, patients with MGMT hypermethylation showed greater responsiveness to radiation therapy. 75 In the brain tumor clinics, nanogram was useful including this epigenetic information. 76 In esophageal cancer, CDO1 methylation was associated with histological grade of neoadjuvant chemotherapy. 36 In tumors that were grade 2/3 after neoadjuvant chemotherapy, CDO1 methylation was not detected. The CDO1 gene is an HRMG in esophageal cancer, so the failure to detect CDO1 methylation in grade 2/3 tumors may represent cancer eradication by neoadjuvant chemotherapy. Issues of concern included cases in which genes exhibited hypomethylation before neoadjuvant chemotherapy, and those in which gene methylation status differed when compared before and after chemotherapy; these disparities will need to be investigated to clarify the clinical utility of screening biopsy samples for gene methylation. In this context, it would be beneficial to exclude patients in whom neoadjuvant chemotherapy was not effective, which would eliminate cases in which disease progresses despite neoadjuvant chemotherapy.
| Intraoperative diagnosis
| Pathological diagnosis
| CON CLUS IONS
Recent research approaches have identified many HRMG in individual human cancers, and these novel emerging epigenetic biomarkers are ready for use in testing liquid biopsies in the clinic. 
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